E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to imatinib

Leukemia and Lymphoma

Volumn 46, Issue 9, 2005, Pages 1375-1377

  Popovici, Cornel ^a   Cailleres, Sylvie ^b   David, Martine ^b   Lafage Pochitaloff, Marina ^a,c   Sainty, Danielle ^a,c   Mozziconacci, Marie Joelle ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b CENTRE HOSPITALIER DU PAYS D AIX   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

BCR exon 5; BCR exon 6; CML; Imatinib; Multiplex PCR; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MESSENGER RNA;

AGED; ARTICLE; CASE REPORT; CHIMERA; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; DNA SPLICING; EXON; GENE DELETION; GENE EXPRESSION; HUMAN; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN BINDING; RECIPROCAL CHROMOSOME TRANSLOCATION;

AGED; EXONS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; PIPERAZINES; PYRIMIDINES;

EID: 24644519908     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500138138     Document Type: Article

References (15)

1. Melo JV. The molecular biology of chronic myeloid leukemia. Leukemia 1990;10:751-756.
2. Saglio G, Guerrasio A, Rosso C, Zaccasia A, Tassinari A, Serra A, Rege-Cambrin G, Mazza U, Gavosto F. New type of BCR-ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990;76:1819-1824.
3. Pane F, Intrieri M, Quintarelli C, Izzo B, Casadei Muccioli G, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002;21:8652-8667.
4. Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukaemia. Leukemia 1999;13:1901-1928.
5. Damaj G, Delabesse E, Le Bihan C, Asnafi V, Rachid M, Lefrere F, Radford-Weiss I, Macintyre E, Hermine O, Varet B. Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol 2002;116:812-816.
6. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-830.
7. Telegeev GD, Dubrovska AN, Dybkov MV, Maliuta SS. Influence of BCR/ABL fusion proteins on the course of Ph leukemias. Acta Biochim Pol 2004;51:845-849.
8. Wang L, Seale J, Woodcock BE, Clark RE. e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts. Leukemia 2002;16:1562-1563.
9. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NC. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chomosome-negative chronic myelogenous leukemia. Blood 1996;88:2236-2240.
10. Dupont M, Jourdan E, Chiesa J. Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML. Leukemia 2000;14:2011-2012.
11. Schultheis B, Wang L, Clarck RE, Melo JV. BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia 2003;17:2054-2055.
12. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease? Haematologica 2004;89:611-613.
13. Hayette S, Tigaud I, Thomas X, French M, Perrin MC, Nicolini F, Michallet M, Magaud JP. Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report. Leukemia 2004;18:1735-1736.
14. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999;189:1399-1412.
15. Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Blood 2000;95:2913-2921.